At IMV, we are accelerating the development of our pipeline and increasing our product candidates through strategic collaborations. We focus on building value for all parties and bringing new options to significant unmet medical needs.

We are actively collaborating with pharmaceutical companies, government agencies, and academic research institutions for research and development. To contact our Business Development team, please use the form in Contact. 

Merck

Multiple collaborations are evaluating our lead candidate, DPX-Survivac, with Merck’s checkpoint inhibitor, Keytruda® pembrolizumab. See our clinical pipeline for more details.

The Wistar Institute

We are involved in a partnership with The Wistar Institute to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Dr. Herlyn’s lab. These gene mutations are the most common cancer-causing mutations in melanoma. They have also been found in other cancers, such as non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas. The project scope includes optimizing the DPX formulation with the BRAF peptides and testing the investigational T cell therapy in pioneering pre-clinical research models at Wistar. IMV holds an exclusive option to in-license intellectual property related to the program.

The Fred Hutchinson Cancer Research Center

IMV and the Fred Hutchinson Cancer Institute partner to develop targeted T cell therapies against multiple new peptide targets. The targets will be identified using technology developed by Dr. Strong’s lab. An initial target for study will be KRAS, a target commonly mutated in many types of cancers, and often associated with poor prognosis and resistance to conventional treatments. The project scope includes optimizing the DPX formulation with the KRAS peptides and testing the investigational T cell therapy in pioneering pre-clinical research models. IMV holds an exclusive option to in-license intellectual property related to the program.